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S U M M A R Y
Background: The number of reported cases of resistance to tigecycline is increasing. The aim of this study
was to evaluate the current standard tigecycline dosage regimen from a pharmacokinetic/
pharmacodynamic (PK/PD) perspective.
Methods: Pharmacokinetic parameters and microbiological data were analyzed by Monte Carlo
simulation in an evaluation of effectiveness.
Results: Tigecycline exhibits excellent in vitro antimicrobial activity, however the standard tigecycline
dosing regimen fails to achieve the best outcome in vivo for the common drug-resistant strains,
including Acinetobacter baumannii, Enterobacter spp, and Klebsiella pneumoniae. This may result in a lack
of response to tigecycline therapy or to a further increase in the resistance rate.
Conclusions: In the absence of new drugs on the horizon, rather than using a single ﬁxed dosing regimen,
tigecycline dosing needs to be optimized in order to achieve the desired successful clinical response and
to prevent an escalation in drug resistance.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Tigecycline, a novel intravenously administered glycylcycline
antibiotic, was approved for the treatment of complicated intra-
abdominal infections (cIAI) and complicated skin and skin-
structure infections (cSSSI) in 2005 by the US Food and Drug
Administration (FDA). This antibiotic has demonstrated an
expanded spectrum of in vitro activity and clinical potency against
Gram-positive and Gram-negative aerobic and anaerobic bacteria,
as well as against antibiotic-resistant strains.1–4 Tigecycline is also
indicated for the treatment of community-acquired bacterial
pneumonia.5 More importantly, Kumarasamy et al.6 have reported
the presence of New Delhi metallo-b-lactamase 1 (NDM-1) among* Corresponding author. Tel.: +86 29 85323241; fax: +86 29 85323240.
E-mail addresses: dongyalin@mail.xjtu.edu.cn, dongyalin@medmail.com.cn
(Y. Dong).
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http://dx.doi.org/10.1016/j.ijid.2013.09.008Gram-negative bacteria, and these bacteria are highly resistant to
all antibiotics except tigecycline and colistin. Tigecycline has been
regarded as the last resort to treat multidrug-resistant (MDR)
bacteria and remains one of the important tools in the manage-
ment of difﬁcult-to-treat infections.
However, several failures of tigecycline therapy have occurred in
recent years, as has been seen in ventilator-associated bacterial
pneumonia (VAP) and other bacterial infections. These failures are
likely due to the development of tigecycline resistance and perhaps
to inadequate dosing. Since 2007, clinical resistance to tigecycline
has been reported in many pathogens, including Acinetobacter spp,
Klebsiella spp, Enterobacter spp, Enterococcus faecalis, Staphylococcus
aureus, Streptococcus pneumoniae, and Serratia marcescens, and
the prevalence of tigecycline resistance has been found to vary
worldwide over the years.7–18 Thus, the use of the only constant
tigecycline dosage regimen against a wide range of bacteria with
variable minimum inhibitory concentrations (MIC) may be ineffec-
tive and lead to a further increase in antibiotic-resistant strains. (The
standard, common dosage regimen for tigecycline for all of these
pathogenic organisms is a 100-mg loading dose, followed by 50 mg
every12 h for at least 5 days and not more than 14 days.19)ociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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uation of the magnitude of efﬁcacy of the empirical tigecycline
dosage regimen for polymicrobial infections is needed. In a model
of murine Acinetobacter baumannii pneumonia, tigecycline efﬁcacy
was predicted successfully by the relationship between the area
under the free concentration–time curve and the MIC (fAUC/
MIC).20 In this study, the ratio of the 24-h area under the
concentration–time curve and the MIC (AUC(0–24)/MIC) was chosen
as the PK/PD index for tigecycline, as this index is considered the
most likely to be predictive of efﬁcacy.21
In the present study, a Monte Carlo simulation was used to
calculate the probability of attaining targeted pharmacodynamic
exposure against a wide range of isolates with variable MICs from
cIAI and cSSSI patients to evaluate the efﬁcacy of the commonly
used tigecycline dosage regimen from a PK/PD perspective. Based
on this, we also compared different therapeutic schemes of
tigecycline to investigate whether the standard dosage regimen
achieves the optimal treatment.
2. Methods
The methodology included: (1) acquisition of pharmacokinetic
parameters and microbiological information, (2) Monte Carlo
simulation, and (3) forming an estimate of the probability of target
attainment (PTA, deﬁned as the probability that at least a speciﬁc
value of a PK/PD index is achieved at a certain MIC) and calculation
of the cumulative fraction of response (CFR, deﬁned as the
expected population probability of target attainment for a speciﬁc
drug dose and a speciﬁc population of microorganisms).22,23
2.1. Pharmacokinetic parameters and microbiological information
The pharmacokinetic parameters of tigecycline were obtained
from published studies.24 The phase 1 studies were randomized,
double-blind, single-center, and placebo-controlled. Pharmaco-
kinetic studies were identiﬁed using the PubMed NLM search
engine for the MEDLINE database. Studies were included if theyTable 1
Frequency distribution of tigecycline MICs for the selected Gram-positive and Gram-n
MIC (mg/l) 
n 0.004 0.008 0.016 0.032 0.064 0.125
Gram-positive pathogens
Staphylococcus aureus 1363 0.37 33.16 49.60
MRSA 286 9.09
Streptococcus agalactiae 308 10.06 18.83 18.18 49.03
Streptococcus anginosus 244 0.41 1.64 3.28 69.67 21.31
Streptococcus constellatus 97 1.03 3.09 86.60 7.22
Streptococcus pyogenes 419 16.23 16.23 52.27 14.32
Streptococcus intermedius 26 3.85 3.85 30.77 34.62 15.38
Enterococcus faecalis 1150 0.26 9.74 44.52 30.96
Enterococcus faecium 799 0.63 19.90 55.69 20.53
Gram-negative pathogens
Escherichia coli 4237 2.08 31.65
Acinetobacter baumannii 299 0.67 8.03 11.37
Citrobacter freundii 215 2.79 1.40 11.16
Citrobacter koseri 203 0.99 18.72
Enterobacter cloacae 894 0.34
Klebsiella oxytoca 613 5.22
Klebsiella pneumoniae 1856 0.05 0.92
Proteus mirabilis 1197 0.17
Pseudomonas aeruginosa 944 0.11
Shigella dysenteriae 159 3.14 35.22
Serratia marcescens 257 
Anaerobic pathogen
Bacteroides fragilis 1663 0.18 0.12 6.37 5.05
MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobia
resistant Staphylococcus aureus; N/A, not available.evaluated clinically relevant dosing regimens and provided the
means for the pharmacokinetic parameters of interest with the
corresponding variability.
In this work, pathogens in the cSSSI and cIAI patient
populations were selected for analysis. Gram-positive pathogens
isolated from the infection site of patients with cIAI and cSSSI
included S. aureus, streptococci, and Enterococcus spp, among
which S. aureus and streptococci were the predominant pathogens
for cSSSI.25 In addition, the isolated pathogenic Gram-negative
and anaerobic bacteria included A. baumannii, Citrobacter spp,
Enterobacter spp, Escherichia coli, Klebsiella spp, Proteus mirabilis,
Pseudomonas aeruginosa, Shigella dysenteriae, S. marcescens, and
Bacteroides fragilis. The predominant pathogens for cIAI were E.
coli and B. fragilis.26 The MIC distributions of the selected Gram-
positive and Gram-negative bacteria isolates were those of the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST). According to EUCAST, the tigecycline MICs for these
pathogens are mainly distributed between 0.004 and 16 mg/l.
Data were obtained from the EUCAST MIC distribution website
(http://www.eucast.org, last accessed April 10, 2013). The
distributions are based on collated data from a total of more
than 24 000 MIC distributions from worldwide sources. The
distributions include MICs from national and international
studies, including resistance surveillance programs (Alexander,
BSAC, ECO-SENS, MYSTIC, NORM, and SENTRY), as well as MIC
distributions from published articles, the pharmaceutical indus-
try, veterinary programs, and individual laboratories. EUCAST
interpretive breakpoints were used for evaluation of the efﬁcacy
of tigecycline.27
2.2. Monte Carlo simulation
The pharmacokinetic parameters were deﬁned as the lognor-
mal distribution obtained with a mean and a percentage coefﬁcient
of variance (CV%); in the case of the MIC, a discrete distribution
ranging from 0.004 to 64 mg/l based on reported data was
considered according to statistical criteria. A Monte Carloegative and anaerobic pathogens from the EUCAST MIC distribution website
Susceptibility
breakpoint (mg/l)
 0.25 0.5 1 2 4 8 16
 15.77 0.81 0.22 0.07 0.5, EUCAST
 76.22 14.34 0.35 0.5, FDA
 3.90 0.25, EUCAST
 3.28 0.41 N/A
 2.06 N/A
 0.72 0.24 0.25, EUCAST
 3.85 3.85 3.85 N/A
 14.00 0.52 0.25, EUCAST
 3.00 0.13 0.13 0.25, EUCAST
 46.50 15.55 3.42 0.52 0.19 0.07 0.02 1.0, EUCAST
 17.06 21.07 20.74 17.06 4.01 2.0, FDA
 46.05 26.05 8.84 2.79 0.93 1.0, EUCAST
 60.59 17.73 1.48 0.49 1.0, EUCAST
 10.96 52.01 26.96 5.70 2.13 1.68 0.22 1.0, EUCAST
 45.02 41.76 5.55 1.63 0.82 1.0, EUCAST
 14.87 49.62 23.11 7.76 3.23 0.32 0.11 1.0, EUCAST
 0.33 2.26 17.71 28.74 36.93 13.62 0.25 N/A
 0.53 0.85 1.69 2.22 12.39 38.98 43.22 N/A
 47.17 11.32 2.52 0.63 N/A
1.56 21.40 63.81 11.28 1.17 0.78 1.0, EUCAST
 13.89 19.36 24.53 18.64 4.75 4.03 3.07 4.0, FDA
l Susceptibility Testing; FDA, US Food and Drug Administration; MRSA, methicillin-
Figure 1. Probability of target attainment as a function of the MIC for 10 000
simulated subjects given tigecycline. The chosen target was AUC(0–24)/MIC >17.9
for complicated skin and skin-structure infection (cSSSI) patients.
Figure 2. Probability of target attainment as a function of the MIC for 10 000
simulated subjects given tigecycline. The chosen target was AUC(0–24)/MIC >6.96
for complicated intra-abdominal infection (cIAI) patients.
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Ball software (Fusion Edition, version 11.1.1.1.00; Oracle).
The steady-state AUC(0–24) data for tigecycline obtained directly
from the selected published study,24 with the dose regimens of
50 mg and 100 mg every 12 h, were 6.14  12% and 9.96  19%
mg.h/ml (mean  CV%), respectively. An AUC(0–24)/MIC >17.925 and
AUC(0–24)/MIC >6.96
26 were the PK/PD targets of tigecycline
identiﬁed by classiﬁcation and regression tree (CART) analysis30 for
the treatment of cSSSI and cIAI, respectively. The corresponding PTA
was calculated with one ﬁxed MIC value ranging from 0.004 to 64 mg/
l, and the calculation of the CFR utilizing the data from the EUCAST
MIC distribution, with a CFR result of >90% representing an optimal
regimen against a population of organisms.
3. Results
Table 1 shows the frequency of MIC distributions of several
signiﬁcant pathogens from cSSSI and cIAI for tigecycline based on
EUCAST data. Differences were investigated for tigecycline
susceptibility among the Gram-positive and Gram-negative
pathogens.
3.1. MIC distribution of Gram-positive pathogens
For the Gram-positive bacteria, 100% of the total isolates
presented MICs 2 mg/l for tigecycline, with 99.54% of the isolates
exhibiting MICs 0.5 mg/l. In total, 4692 Gram-positive bacteria
isolates were collected during this study, with 1363 S. aureus
isolates, 286 methicillin-resistant S. aureus (MRSA) isolates, and
1949 Enterococcus spp isolates showing a high level of susceptibil-
ity to tigecycline (99.71%, 99.65%, and 99.62%, respectively).
Similar susceptibility rates of Streptococcus agalactiae and Strepto-
coccus pyogenes were recorded for tigecycline (100% and 99.76%
susceptible, respectively). The susceptibility breakpoints for the
other Streptococcus spp isolates to tigecycline were not available
(Table 1).
3.2. MIC distribution of Gram-negative and anaerobic pathogens
For the Gram-negative and anaerobic bacteria, the correspond-
ing MIC values for Citrobacter koseri and S. dysenteriae were 2 mg/
l; for A. baumannii and Klebsiella oxytoca were 4 mg/l; for
Citrobacter freundii and S. marcescens were 8 mg/l; and for E. coli,
Enterobacter cloacae, Klebsiella pneumoniae, P. mirabilis, P. aerugi-
nosa, and B. fragilis were 16 mg/l. A total of 10 874 Gram-negative
isolates were collected during this study. High tigecycline
susceptibility rates of 99.20%, 97.90%, and 97.55% were found
for E. coli, Citrobacter spp, and K. oxytoca strains, respectively. A.
baumannii and B. fragilis had relatively lower susceptibility
compared with the aforementioned strains, of 95.99% and 92.9%,
respectively. However, signiﬁcant decreases in tigecycline suscep-
tibility were noted in strains of E. cloacae (90.27%), K. pneumonia
(88.57%), and S. marcescens (86.77%). The susceptibility break-
points of P. mirabilis, P. aeruginosa, and S. dysenteriae isolates to
tigecycline were not available (Table 1).
3.3. PTA analysis
Figures 1 and 2 show the probability of PK/PD target attainment
by MIC for the antibiotic studied at the selected dosing regimens.
On the basis of simulation results, the use of tigecycline 50 mg or
100 mg every 12 h provided a PTA (AUC(0–24)/MIC >17.9, for cSSSI)
higher than 99% for MICs 0.25 mg/l. With the dose regimens of
50 mg and 100 mg every 12 h, respectively, the corresponding PTA
values were 0% and 67.98% for a MIC of 0.5 mg/l. The PTA values
remained at zero for a MIC higher than 0.5 mg/l (Figure 1).The selected targets for cIAI were AUC(0–24)/MIC >6.96, and the
tigecycline dosage regimens of 50 mg and 100 mg every 12 h both
provided PTA values of 100% for a MIC 0.5 mg/l. Different PTA
values were demonstrated between 50 mg and 100 mg every 12 h
for a MIC of 1 mg/l, with values of 12.93% and 96.6%, respectively.
The PTA values remained at zero for a MIC higher than 2 mg/l
(Figure 2).
3.4. CFR analysis
Table 2 shows the assessment of CFR for different tigecycline
dosage regimens evaluated based on the AUC(0–24)/MIC >17.9 in
the treatment of cSSSI and the AUC(0–24)/MIC >6.96 in the
treatment of cIAI. Regarding Gram-positive bacteria isolated from
cSSSI patients, average CFR values of higher than 90% were
obtained with the use of the standard dose regimen 50 mg every
12 h (97.50%) and the higher dose of 100 mg every 12 h (99.17%).
Whilst the values of CFR for the MRSA isolates (84.81%) and S.
dysenteriae isolates (85.22%) with the dose of 50 mg every 12 h
were lower than 90%, the corresponding CFR values remained
higher than 90% when the dose was augmented to 100 mg every
12 h. Signiﬁcant decreases in CFRs were noted in the Gram-
negative bacteria isolates from cSSSI patients, showing a total
mean value of 38.44% and 54.67%, with 50 mg and 100 mg every
12 h doses, respectively. Tigecycline was rarely active against P.
mirabilis strains (CFR varied from 0.5% to 2.05%), P. aeruginosa
strains (CFR varied from 0.64% to 1.22%), and S. marcescens (CFR
varied from 1.66% to 16.28%) on the basis of the varied dose
regimens.
CFR values obtained with tigecycline (AUC(0–24)/MIC >6.96, for
cIAI) are shown in Table 2. The average CFR values of Gram-positive
Table 2
Expected cumulative fraction of response (CFR) for tigecycline. The chosen targets were AUC(0–24)/MIC >17.9 for complicated skin and skin-structure infection (cSSSI)
patients and AUC(0–24)/MIC >6.96 for complicated intra-abdominal infection (cIAI) patients.
a
Pathogens Probability (%)
AUC(0–24)/MIC >17.9
Probability (%)
AUC(0–24)/MIC >6.96
50 mg q12h 100 mg q12h 50 mg q12h 100 mg q12h
Gram-positive pathogens
Staphylococcus aureus 98.80 99.45 99.74 99.92
MRSA 84.81 95.06 - -
Streptococcus agalactiae 99.97 100.0 100.0 100.0
Streptococcus anginosus 99.57 99.87 100.0 100.0
Streptococcus constellatus 97.94 99.34 100.0 100.0
Streptococcus pyogenes 99.77 99.93 - -
Streptococcus intermedius - - 96.67 99.89
Enterococcus faecalis 99.39 99.83 - -
Enterococcus faecium 99.73 99.84 - -
Gram-negative pathogens
Escherichia coli 79.92 90.80 96.22 99.10
Acinetobacter baumannii 37.02 51.47 - -
Citrobacter freundii 61.10 79.12 88.59 96.07
Citrobacter koseri 79.90 92.35 98.22 99.47
Enterobacter cloacae 11.23 46.68 66.80 89.51
Klebsiella oxytoca 49.94 78.63 92.72 97.41
Klebsiella pneumoniae 15.74 49.59 68.45 88.00
Proteus mirabilis 0.50 2.05 - -
Pseudomonas aeruginosa 0.64 1.22 - -
Shigella dysenteriae 85.22 93.23 - -
Serratia marcescens 1.66 16.28 - -
Anaerobic pathogens
Bacteroides fragilis - - 48.14 69.18
AUC, area under the curve; MIC, minimum inhibitory concentration; q12 h, every 12 h; MRSA, methicillin-resistant Staphylococcus aureus.
a ‘-’, no corresponding pathogen isolated from the infection site of patients.
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100 mg every 12 h. The CFR value of C. freundii (88.59%) was only
fractionally lower than 90%. Among the remaining isolates, the
CFRs of E. cloacae, K. pneumoniae, and B. fragilis were noted to be
lower (66.8%, 68.45%, and 48.14%, respectively) with 50 mg every
12 h, and still presented CFRs lower than 90% with the augmented
dose of 100 mg every 12 h. CFR values gradually increased with the
increase in tigecycline dosing and the reduction in the PD
breakpoint (Table 2).
4. Discussion
In the current study, the in vitro activity of tigecycline was
assessed against a selection of important Gram-positive and Gram-
negative pathogens collected from cSSSI and cIAI patients.
Although pathogens isolated from the infection sites of patients
were demonstrated to have a varied MIC distribution, they still
presented a high level of susceptibility to tigecycline: all wild-type
Gram-positive pathogens with available MIC breakpoints had a
susceptibility higher than 99%, and for Gram-negative pathogens,
this was lower but they were still susceptible to tigecycline.
According to Kahlmeter et al.,27 the tigecycline MIC values for wild-
type staphylococci, streptococci, E. faecalis, and Enterococcus
faecium were all 0.5 mg/l in 2006. In this study, 99.17% of these
Gram-positive isolates exhibited MICs 0.5 mg/l, and 0.29% of S.
aureus pathogens and 0.13% of E. faecium pathogens presented
MICs 1 mg/l; this illustrates the slowly increasing emergence of
antimicrobial resistance in these pathogens over the years.
Figures 1 and 2 show that as the tigecycline dose increased, the
corresponding theoretical MIC breakpoint, above which the
treatment for infection would be ineffective, also improved. For
patients with cSSSI, the best treatment outcome was achieved
using the standard regimen for all of the Gram-positive pathogens
except MRSA, but this failed for all the Gram-negative ones. With
the increased dose (100 mg every 12 h) treatment, an optimal dosewas obtained for all Gram-positive bacteria including MRSA. The
CFR values of Gram-negative bacteria increased markedly, but still
the majority were less than 90% with 100 mg every 12 h. In
addition, we directly observed that P. mirabilis, P. aeruginosa, and S.
marcescens failed to respond to tigecycline; combination therapy
may be suggested for such polymicrobial infections as a result of
the studies carried out in vitro and in animal models.31–33 For
patients with cIAI, an optimal therapy was achieved against most
of the pathogens, however the doses of 50 mg and 100 mg every
12 h both remained poorly active against B. fragilis.
With the investigation of tigecycline susceptibility in numerous
selected pathogens, tigecycline was found to be one of the most
active antimicrobial agents against Gram-positive isolates and also
to be effective against Gram-negative ones in vitro, including drug-
resistant pathogens. However we also demonstrated that the
common drug-resistant strains failed to attain best treatment with
the current standard tigecycline dose regimen. This is in
concordance with the results of several clinical studies. Consales
et al.34 described an MDR A. baumannii (MRAB) outbreak that
occurred in the intensive care unit of Prato Hospital in June to
August 2009. In that study tigecycline resulted in a rapid recovery,
but resistance nevertheless ensued. Similar reports35–38 have given
evidence that tigecycline has a degree of clinical effectiveness in
the treatment of complicated infections with MDR strains,
however resistance was documented to have occurred in the
patients and might have resulted from inappropriate tigecycline
dosing. Furthermore, although the efﬁcacy of tigecycline is well-
known, we believe that tigecycline is not the best choice in some
cases. In the case of VAP, failure of tigecycline is not only related to
the enhanced MIC of some MDR bacteria such as A. baumannii, but
also to a decrease in AUC(0–24).
39 According to Burkhardt et al.,40
alveolar cell concentrations are high but extracellular epithelial
lining ﬂuid concentrations of tigecycline are insufﬁcient to reliably
eradicate extracellular bacteria in the case of a mechanically
ventilated patient. Therefore, the current dosage of 50 mg
J. Xie et al. / International Journal of Infectious Diseases 18 (2014) 62–6766tigecycline twice daily is probably an under-dose for the treatment
of pneumonia caused by typical, extracellular-acting bacteria.
Meanwhile, it is noted that the higher dose regimen may not be
tolerated due to gastrointestinal side effects, which is also an
important factor in discussing optimal tigecycline dosing. Tigecy-
cline might not be the best choice for infections that cannot be
effectively treated with the standard dose and where a higher dose
cannot be tolerated.
To guarantee clinical success with conventional tigecycline
therapy, based on the ﬁndings and limitations of this study, we can
conclude that: (1) With MICs 0.25 mg/l, the use of standard
tigecycline dosing is predicted to have a good clinical outcome at
AUC0–24/MIC >17.9 for cSSSI patients, whilst with MICs 0.5 mg/l,
the desired clinical outcome is predicted at AUC0–24/MIC >6.96 for
cIAI patients when applying the same dose of tigecycline. In this
regard, optimization of the current tigecycline dose use is
unavoidable for more effective treatment. (2) Our study revealed
the current standard tigecycline dosing regimen to be excellent for
Gram-positive infections. The recommendation of tigecycline
courses for the treatment of Gram-negative infections with regard
to whether tigecycline empirical treatment should be retained or
adjusted, should be based on the value of the expected CFR and
other factors. (3) Finally, this study reinforces the idea of
considering not only the antimicrobial MIC distribution but also
the PK/PD index of AUC0–24/MIC ratios to increase the probability
of clinical success in the treatment of patients with different
infections.
Further work needs to focus on the optimization of tigecycline
dose regimens for the treatment of different infections with
speciﬁc pathogens. Rational drug use is important to prevent an
escalation in antimicrobial resistance and to maximize the
likelihood of a favorable clinical response, as well as to minimize
the probability of exposure-related toxicity.
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